NCT07335965 Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia
| NCT ID | NCT07335965 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Borrelia Recurrentis Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-02-19 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2025-02-19 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species. A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.
Eligibility Criteria
Inclusion Criteria: * Minor or adult subject * Having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg Exclusion Criteria: \- Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07335965 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Borrelia Recurrentis Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07335965 currently recruiting?
Yes, NCT07335965 is actively recruiting participants. Contact the research team at emilie.talagrandreboul@chru-strasbourg.fr for enrollment information.
Where is the NCT07335965 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07335965 clinical trial?
NCT07335965 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 25 participants.